IMNN | Imunon, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.6500 - 0.6949
52 Week Range	0.4800 - 3.65
Beta	1.97
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	241,959
Average Volume	232,676
Shares Outstanding	14,500,700
Market Cap	9,918,479
Sector	Healthcare
Industry	Biotechnology
IPO Date	1999-03-01

Valuation
Profitability
Growth
Health
P/E Ratio	-0.36
Forward P/E Ratio	N/A
EPS	-1.91
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	33
Country	USA
Website	IMNN

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

IMNN's peers: XCUR, CYCC, HSTO, DMAC, NLTX, SNTI, HILS, SABS, QNRX, SABSW, CING, BLCM, LSTA, LIXT, KA, TOVX, LUMO, DFFN, AVTX, CBIO

*Chart delayed

Analyzing fundamentals for IMNN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see IMNN Fundamentals page.

Watching at IMNN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on IMNN Technicals page.